Showing 6841-6850 of 10618 results for "".
- Five Grand Challenges for the Future at the Interface of Engineering and Medicinehttps://reachmd.com/news/five-grand-challenges-for-the-future-at-the-interface-of-engineering-and-medicine/2457327/These research areas — part of the Convergence Revolution — have the greatest potential of achieving tremendous impact on the field of medicine in the coming decades or century. Jianyi "Jay" Zhang, M.D., Ph.D.,Just imagine this,
- Study Finds Raised Blood Pressure Is the Leading Risk Factor for Death in Australiahttps://reachmd.com/news/study-finds-raised-blood-pressure-is-the-leading-risk-factor-for-death-in-australia/2457260/The ranking in the contribution of risk factors towards all-cause, CVD, IHD and stroke deaths by males and females in 1990, 2010, and 2019, with percentage change and 95% UI in age-standa
- The Experience of Receiving a Letter from a Cancer Genetics Clinic About Risk for Hereditary Cancerhttps://reachmd.com/news/the-experience-of-receiving-a-letter-from-a-cancer-genetics-clinic-about-risk-for-hereditary-cancer/2457282/We invited 15 at-risk relatives, one of whom accepted the invitation but did not answer the calls from the first author, and 14 of whom ultimately were interviewed. Participant characteristics are given in Table
- Sylvester Appoints Prominent Oncologist-Researcher to Lead Transplantation and Cellular Therapyhttps://reachmd.com/news/sylvester-appoints-prominent-oncologist-researcher-to-lead-transplantation-and-cellular-therapy/2457224/Newswise — MIAMI, FLORIDA (Feb. 16, 2024) – Prominent oncologist and researcher Damian Green, M.D., will join
- Leading Valley Fever Expert Shares ‘State-of-the-Art’ Knowledge About Fungal Diseasehttps://reachmd.com/news/leading-valley-fever-expert-shares-state-of-the-art-knowledge-about-fungal-disease/2457217/A University of Arizona College of Medicine – Tucson researcher and internationally recognized expert on Valley fever co-authored a review paper, published earlier this month
- Promising Target for CAR T-Cell Therapy Leads to Potent Antitumor Responses Against Cutaneous and Rare Melanomashttps://reachmd.com/news/promising-target-for-car-t-cell-therapy-leads-to-potent-antitumor-responses-against-cutaneous-and-rare-melanomas/2457214/Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have built and demonstrated the potential efficacy of a new chimeric antigen receptor (CAR) T-cell-based immunotherapy specifically designed to treat patients with cutaneous and rare subtypes of melanoma.CAR
- Johns Hopkins Medicine-Led Study Shows Rapid COVID-19 Tests Done at Home Are Reliablehttps://reachmd.com/news/johns-hopkins-medicine-led-study-shows-rapid-covid-19-tests-done-at-home-are-reliable/2457188/In a study involving nearly 1,000 patients seen at the Baltimore Convention Center Field Hospital (BCCFH) during a five-month period in 2022 — researchers at Johns Hopkins Medicine, the University of Maryland School of Medicine and five other collaborators repor
- Scientists Develop New Technology to Identify Individual Full-Length Human Proteinshttps://reachmd.com/news/scientists-develop-new-technology-to-identify-individual-full-length-human-proteins/2457194/The illustration shows a human protein and amino acid code in the background. The new FRET X technology is capable of identifying proteins using protein fingerprints. The Chirlmin Joo Lab ob
- Study Reveals Mechanism That Aggravates Tuberculosis and Reduces Survival Rateshttps://reachmd.com/news/study-reveals-mechanism-that-aggravates-tuberculosis-and-reduces-survival-rates/2457121/Tuberculosis (TB) is a highly infectious disease caused by the bacterium Mycobacterium tuberculosis. It primarily affects the lungs but can also affect other parts of the body. According to the World Health Organization (WHO), TB is one of the top 10
- Yale-Led Research Explains Why Many Cancer Drugs Fail During Clinical Trial Testinghttps://reachmd.com/news/yale-led-research-explains-why-many-cancer-drugs-fail-during-clinical-trial-testing/2457108/Cancer drugs often don't behave as expected in clinical trials. A study published Oct. 11 in the journal Cell Chemical Biology explores why drugs under development are